

**Table SI. Results of immunohistochemical analysis of placental growth factor (PIGF) and vascular endothelial growth factor-A (VEGF-A) in 28 patients with mycosis fungoides/Sézary syndrome (MF/SS)**

| Age, years | Sex | Diagnosis        | Stage | PIGF |    |    | VEGF-A |    |
|------------|-----|------------------|-------|------|----|----|--------|----|
|            |     |                  |       | KC   | EC | TC | EC     | TC |
| 61         | M   | Patch MF         | IA    | ±    | +  | -  | ±      | -  |
| 56         | M   | Patch MF         | IA    | ±    | -  | ±  | ±      | ±  |
| 70         | M   | Patch MF         | IB    | ±    | ±  | -  | +      | -  |
| 38         | M   | Patch MF         | IA    | +    | ±  | ±  | +      | ±  |
| 52         | M   | Patch MF         | IA    | +    | -  | ±  | +      | ±  |
| 59         | F   | Patch MF         | IB    | -    | ±  | -  | +      | ±  |
| 62         | M   | Plaque MF        | IB    | +    | ±  | -  | ±      | +  |
| 64         | M   | Plaque MF        | IA    | +    | -  | -  | ±      | +  |
| 65         | F   | Plaque MF        | IB    | ±    | ±  | -  | ±      | +  |
| 64         | M   | Plaque MF        | IA    | -    | -  | -  | +      | ±  |
| 31         | F   | Plaque MF        | IA    | +    | -  | ±  | +      | +  |
| 27         | F   | Plaque MF        | IB    | +    | +  | ±  | +      | ±  |
| 50         | F   | Plaque MF        | IB    | +    | +  | ±  | +      | ±  |
| 74         | M   | Plaque MF        | IB    | ++   | ±  | ±  | +      | ±  |
| 62         | M   | Plaque MF        | IB    | ++   | +  | +  | +      | ++ |
| 57         | M   | Tumour MF        | IIB   | +    | +  | ±  | +      | ±  |
| 45         | M   | Tumour MF        | IIB   | +    | ±  | -  | +      | ±  |
| 61         | M   | Tumour MF        | IIB   | +    | ±  | ±  | +      | ±  |
| 38         | F   | Tumour MF        | IIB   | ±    | +  | +  | +      | +  |
| 40         | M   | Tumour MF        | IIB   | +    | +  | ±  | +      | +  |
| 40         | M   | Erythrodermic MF | IIIA  | ±    | +  | +  | +      | +  |
| 30         | F   | Erythrodermic MF | IIIA  | ++   | +  | ±  | +      | +  |
| 52         | M   | SS               | IVA1  | ±    | -  | -  | +      | ±  |
| 58         | F   | SS               | IVA1  | +    | ±  | -  | +      | ±  |
| 64         | F   | SS               | IVA1  | ±    | ±  | ±  | +      | ++ |
| 42         | M   | SS               | IVA1  | +    | +  | ±  | +      | +  |
| 42         | F   | SS               | IVA1  | ±    | ±  | -  | +      | ±  |
| 67         | M   | SS               | IVA1  | +    | +  | +  | ±      | +  |

KC: keratinocytes; EC: endothelial cells; TC: tumour cells; MF: mycosis fungoides; SS: Sézary syndrome. The following grading system was used for keratinocytes and endothelial cells: - negative; ± slight staining; + moderate staining; ++ strong staining. For tumour cells, we used the following grading system: - negative; ± > 0-25% of tumour cells stained; + > 25-50% tumour cells stained; ++ > 50% tumour cells stained.